Certara, Inc.
Unless otherwise indicated, references to the “Company,” “Certara,” “we,” “us” and “our” refer to Certara, Inc. and its consolidated subsidiaries.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K (this “Annual Report”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements (other than statements of historical facts) in this Annual Report regarding the prospects of the industry and our prospects, plans, financial position and business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “should,” “expect,” “might,” “intend,” “will,” “estimate,” “anticipate,” “plan,” “believe,” “predict,” “potential,” “continue,” “suggest,” “project” or “target” or the negatives of these terms or variations of them or similar terminology. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. The following factors are among those that may cause actual results to differ materially from the forward-looking statements:
| ● | our ability to compete within our market; |
| ● | any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; |
| ● | the occurrence of natural disasters and epidemic diseases, including the ongoing COVID 19 pandemic, which may result in delays or cancellations of customer contracts or decreased utilization by our employees; |
| ● | changes or delays in government regulation relating to the biopharmaceutical industry; |
| ● | increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; |
| ● | trends in research and development (“R&D”) spending, the use of third parties by biopharmaceutical companies and a shift toward more R&D occurring at smaller biotechnology companies; |
| ● | our ability to successfully enter new markets, increase our customer base and expand our relationships with existing customers; |
| ● | our ability to retain key personnel or recruit additional qualified personnel; |
| ● | consolidation within the biopharmaceutical industry; |
| ● | reduction in the use of our products by academic institutions; |
| ● | pricing pressures due to increased customer utilization of our products; |
| ● | any delays or defects in our release of new or enhanced software or other biosimulation tools; |
| ● | failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by our existing customers; |
| ● | our ability to accurately estimate costs associated with our fixed-fee contracts; |
| ● | risks related to our contracts with government customers, including the ability of third parties to challenge our receipt of such contracts; |
| ● | our ability to sustain recent growth rates; |
| ● | any future acquisitions and our ability to successfully integrate such acquisitions; |
| ● | the accuracy of our addressable market estimates; |
| ● | the length and unpredictability of our software and service sales cycles; |
| ● | our ability to successfully operate a global business; |
| ● | our ability to comply with applicable anti-corruption, trade compliance and economic sanctions laws and regulations; |
| ● | risks related to litigation against us; |